Biogen beats Novo to the punch
Biogen and the Danish drug-giant Novo Nordisk are locked in a race to access the hemophilia market first – a market that could yield billions. According to an industry analyst, it looks as if the US biotech company has beaten the Novo to the punch with its long-acting hemophilia drug.
Biogen Idec and Novo Nordisk both have a potential blockbuster for the treatment of hemophilia A in their pipelines – a market believed to have a potential of just about 30 billion Danish kroner, or 500 million dollars.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Analysts: This is where Novo can stand out
For abonnenter
